0001493152-22-014659.txt : 20220520 0001493152-22-014659.hdr.sgml : 20220520 20220520181557 ACCESSION NUMBER: 0001493152-22-014659 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220518 FILED AS OF DATE: 20220520 DATE AS OF CHANGE: 20220520 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mack Anthony P. CENTRAL INDEX KEY: 0001818483 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40064 FILM NUMBER: 22949107 MAIL ADDRESS: STREET 1: C/O VIRPAX PHARMACEUTICALS, INC. STREET 2: 1554 PAOLI PIKE #279 CITY: WEST CHESTER STATE: PA ZIP: 19380 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Virpax Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001708331 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 821510982 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1554 PAOLI PIKE #279 CITY: WEST CHESTER STATE: PA ZIP: 19380 BUSINESS PHONE: 484-875-3195 MAIL ADDRESS: STREET 1: 1554 PAOLI PIKE #279 CITY: WEST CHESTER STATE: PA ZIP: 19380 FORMER COMPANY: FORMER CONFORMED NAME: Virpax Pharmaceuticals Inc. DATE OF NAME CHANGE: 20170602 4 1 ownership.xml X0306 4 2022-05-18 0 0001708331 Virpax Pharmaceuticals, Inc. VRPX 0001818483 Mack Anthony P. 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 1 1 0 0 Chief Executive Officer Common Stock, $0.00001 par value 2022-05-18 4 P 0 75750 1.34 A 252562 D Common Stock, $0.00001 par value 2730438 I By Virpax Pharmaceuticals, LLC The price reported in Column 4 is a weighted average price. These shares of Common Stock were purchased in multiple transactions at prices ranging from $1.32 to $1.37 per share, inclusive. The Reporting Person undertakes to provide to Virpax Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. The Reporting Person owns 88.8888% of the outstanding member units of Virpax Pharmaceuticals, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein. /s/ Christopher Chipman, attorney-in-fact 2022-05-20